Papillary urothelial neoplasm of low malignant potential (PUN-LMP)

Autor: Karin Plass, Virginia Hernández, Richard Sylvester, H.M. Bruins, Anouk E. Hentschel, Nicolai A. Huebner, Isabel Alemany, Johannes Breyer, Dimitrios Volanis, Morgan Rouprêt, Luca Lunelli, Judith Bosschieter, Shahrokh F. Shariat, Marko Babjuk, Matthias Evert, David Ashabere, Sebastian Mannweiler, J.D. Subiela Henríquez, Jakko A. Nieuwenhuijzen, Venkata R.M. Kusuma, T.H. Van Der Kwast, Alexandre R. Zlotta, Laura S. Mertens, Olivier Cussenot, Lenka Bauerová, Jaromir Hacek, Andrea Haitel, A.G. Van Der Heijden, James N'Dow, B.W.G. Van Rhijn, A. Scavarda-Lamberti, E. de la Peña, Daniel Cohen, Eva Compérat, S. El Sheikh, Willemien Runneboom, Jean François Coté, Joan Palou, Antonin Brisuda, Maximilian Seles, José Rubio-Briones, Oscar Rodríguez, A.H. Mostafid, Michael Pešl, Viktor Soukup, Johannes Bründl, Diana Turturica, Francesca Pisano, Paolo Gontero, Carlos Llorente, Ferran Algaba, Lambertus A. Kiemeney, C.A. Hulsbergen Van De Kaa, Otakar Čapoun, Ana Calatrava, Francesco Soria, Sonja Herdegen, Richard Zigeuner, Juliette Cotte, J. Domínguez-Escrig, Maximilian Burger, Luca Molinaro
Přispěvatelé: Urology, CCA - Cancer Treatment and quality of life, Other Research
Jazyk: angličtina
Rok vydání: 2020
Předmět:
Male
Canada
Pathology
medicine.medical_specialty
Bladder
Grade
Urology
030232 urology & nephrology
Carcinomas
World health
Lesion
WHO
03 medical and health sciences
0302 clinical medicine
All institutes and research themes of the Radboud University Medical Center
Urothelial
Urological cancers Radboud Institute for Molecular Life Sciences [Radboudumc 15]
Cancer
Nonmuscle-invasive
medicine
Humans
Neoplasm Invasiveness
Cumulative incidence
Papillary urothelial neoplasm of low malignant potential
Pathological
Aged
Retrospective Studies
Observer Variation
Carcinoma
Transitional Cell
business.industry
Non invasive
Patient data
Middle Aged
medicine.disease
Carcinoma
Papillary
Europe
Urinary Bladder Neoplasms
Oncology
Time to recurrence
030220 oncology & carcinogenesis
Urological cancers Radboud Institute for Health Sciences [Radboudumc 15]
Female
Neoplasm Grading
Neoplasm Recurrence
Local
medicine.symptom
business
Zdroj: Urologic Oncology-Seminars and Original Investigations, 38, 5, pp. 440-448
UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Urologic Oncology-Seminars and Original Investigations, 38, 440-448
Hentschel, A E, van Rhijn, B W G, Bründl, J, Compérat, E M, Plass, K, Rodríguez, O, Henríquez, J D S, Hernández, V, de la Peña, E, Alemany, I, Turturica, D, Pisano, F, Soria, F, Čapoun, O, Bauerová, L, Pešl, M, Bruins, H M, Runneboom, W, Herdegen, S, Breyer, J, Brisuda, A, Scavarda-Lamberti, A, Calatrava, A, Rubio-Briones, J, Seles, M, Mannweiler, S, Bosschieter, J, Kusuma, V R M, Ashabere, D, Huebner, N, Cotte, J, Mertens, L S, Cohen, D, Lunelli, L, Cussenot, O, Sheikh, S E, Volanis, D, Coté, J-F, Rouprêt, M, Haitel, A, Shariat, S F, Mostafid, A H, Nieuwenhuijzen, J A, Zigeuner, R, Dominguez-Escrig, J L, Hacek, J, Zlotta, A R, Burger, M, Evert, M, Hulsbergen-van de Kaa, C A, van der Heijden, A G, Kiemeney, L A L M, Soukup, V, Molinaro, L, Gontero, P, Llorente, C, Algaba, F, Palou, J, N'Dow, J, Babjuk, M, van der Kwast, T H & Sylvester, R J 2020, ' Papillary urothelial neoplasm of low malignant potential (PUN-LMP) : Still a meaningful histo-pathological grade category for Ta, noninvasive bladder tumors in 2019? ', Urologic Oncology, vol. 38, no. 5, doi: 10.1016/j.urolonc.2019.10.002, pp. 440-448 . https://doi.org/10.1016/j.urolonc.2019.10.002
Urologic Oncology, 38(5):doi: 10.1016/j.urolonc.2019.10.002, 440-448. Elsevier Inc.
ISSN: 1078-1439
Popis: Background: Papillary urothelial neoplasm of low malignant potential (PUN-LMP) was introduced as a noninvasive, noncancerous lesion and a separate grade category in 1998. Subsequently, PUN-LMP was reconfirmed by World Health Organization (WHO) 2004 and WHO 2016 classifications for urothelial bladder tumors. Objectives: To analyze the proportion of PUN-LMP diagnosis over time and to determine its prognostic value compared to Ta-LG (low-grade) and Ta-HG (high-grade) carcinomas. To assess the intraobserver variability of an experienced uropathologist assigning (WHO) 2004/2016 grades at 2 time points. Materials and methods: Individual patient data of 3,311 primary Ta bladder tumors from 17 hospitals in Europe and Canada were available. Transurethral resection of the tumor was performed between 1990 and 2018. Time to recurrence and progression were analyzed with cumulative incidence functions, log-rank tests and multivariable Cox-regression stratified by institution. Intraobserver variability was assessed by examining the same 314 transurethral resection of the tumorslides twice, in 2004 and again in 2018. Results: PUN-LMP represented 3.8% (127/3,311) of Ta tumors. The same pathologist found 71/314 (22.6%) PUN-LMPs in 2004 and only 20/314 (6.4%) in 2018. Overall, the proportion of PUN-LMP diagnosis substantially decreased over time from 31.3% (1990-2000) to 3.2% (2000-2010) and to 1.1% (2010-2018). We found no difference in time to recurrence between the three WHO 2004/2016 Ta-grade categories (log-rank, P = 0.381), nor for LG vs. PUN-LMP (log-rank, P = 0.238). Time to progression was different for all grade categories (log-rank, P < 0.001), but not between LG and PUN-LMP (log-rank, P = 0.096). Multivariable analyses on recurrence and progression showed similar results for all 3 grade categories and for LG vs. PUN-LMP. Conclusions: The proportion of PUN-LMP has decreased to very low levels in the last decade. Contrary to its reconfirmation in the WHO 2016 classification, our results do not support the continued use of PUN-LMP as a separate grade category in Ta tumors because of the similar prognosis for PUN-LMP and Ta-LG carcinomas. (C) 2019 Elsevier Inc. All rights reserved.
Databáze: OpenAIRE
Externí odkaz: